Chimeric Therapeutics Ltd
ASX:CHM

Watchlist Manager
Chimeric Therapeutics Ltd Logo
Chimeric Therapeutics Ltd
ASX:CHM
Watchlist
Price: 0.004 AUD Market Closed
Market Cap: 14.6m AUD

Net Margin
Chimeric Therapeutics Ltd

-262.8%
Current
-38%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-262.8%
=
Net Income
-10.4m
/
Revenue
4m

Net Margin Across Competitors

No Stocks Found

Chimeric Therapeutics Ltd
Glance View

Market Cap
14.6m AUD
Industry
Biotechnology

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.

CHM Intrinsic Value
0.007 AUD
Undervaluation 43%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-262.8%
=
Net Income
-10.4m
/
Revenue
4m
What is the Net Margin of Chimeric Therapeutics Ltd?

Based on Chimeric Therapeutics Ltd's most recent financial statements, the company has Net Margin of -262.8%.

Back to Top